Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HK2 | P52789 | 5/20 | 0.45 |
| ▸ | HK1 | P19367 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PYGB | P11216 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Streptozosin SCHEMBL444089 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL18402590 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL4748 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL13840968 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL15012795 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL10201155 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL17328035 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL10262780 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL18402588 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL444088 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180216063-A1 | THREE-DIMENSIONAL VASCULAR NETWORK ASSEMBLY FROM INDUCED PLURIPOTENT STEM CELLS | THE JOHNS HOPKINS UNIVERSITY | 2018-08-02 | — | — | US | disclosed |
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-20170273988-A1 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-09-28 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273988-A1 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | BCL6, BCL6B, BCL9 | LMNA 2332/4885KDM4E 783/4885CYP2D6 322/4885 |
| US-20180216063-A1 | THREE-DIMENSIONAL VASCULAR NETWORK ASSEMBLY FROM INDUCED PLURIPOTENT STEM CELLS | HIF1A, EGLN3, EPAS1 | LMNA 2204/4885KDM4E 658/4885CYP2D6 4813/4885 |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | LMNA 2800/4885KDM4E 3389/4885CYP2D6 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.